COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: 19205

Trial Status: Open
Disease Type: Lymphoma
Trial ID 19205
Sponsor ID TGI Therapeutics

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Principal Investigator
Mitul Gandhi, MD
5 Locations

Locations

Fairfax Office

Alexandria Office

Arlington Office

Gainesville Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 18263
Sponsor ID Beigene

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 18013
Sponsor ID Seattle Genetics, Inc.

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects .  Ph2 A+AVD +G-CSF or AOAD in CHL

Principal Investigator
Mitul Gandhi, MD
5 Locations